The company's nascent revenue of $510,360 is currently constrained by a 30.44% gross margin, which reflects the high costs associated with specialized laboratory labor and reagents.
| Metric | Dec'24 | Dec'23 |
|---|
| Sales/Revenue | 510.36K | 350.13K |
| Revenue Growth % | 45.76% | - |
| Cost of Goods Sold | 355K | 196.69K |
| COGS % of Revenue | 69.56% | 56.17% |
| Gross Profit | 155.36K | 153.44K |
| Gross Margin % | 30.44% | 43.82% |
| Gross Profit Growth % | 1.25% | - |
| Operating Expenses | 1.62M | 163.29K |
| OpEx % of Revenue | 316.89% | 46.64% |
| Selling, General & Admin | 1.13M | 160.56K |
| SG&A % of Revenue | 220.71% | 45.86% |
| Research & Development | 491.35K | 0 |
| R&D % of Revenue | 96.28% | - |
| Other Operating Expenses | -493 | 2.73K |
| Operating Income | -1.46M | -9.85K |
| Operating Margin % | -286.45% | -2.81% |
| Operating Income Growth % | -14746.45% | - |
| EBITDA | -1.36M | -7.39K |
| EBITDA Margin % | -265.93% | -2.11% |
| EBITDA Growth % | -18252.87% | - |
| D&A (Non-Cash Add-back) | 104.73K | 2.45K |
| EBIT | -1.39M | 19.79K |
| Net Interest Income | 11.04K | -1.85K |
| Interest Income | 11.81K | 290 |
| Interest Expense | 772 | 2.14K |
| Other Income/Expense | 75.45K | 27.5K |
| Pretax Income | -1.39M | 17.65K |
| Pretax Margin % | -271.67% | 5.04% |
| Income Tax | 25.08K | 4.09K |
| Effective Tax Rate % | -1.81% | 23.17% |
| Net Income | -1.41M | 13.56K |
| Net Margin % | -276.58% | 3.87% |
| Net Income Growth % | -10509.73% | - |
| Net Income (Continuing) | -1.41M | 13.56K |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | 0.00 | 0.00 |
| EPS Growth % | - | - |
| EPS (Basic) | 0.00 | 0.00 |
| Diluted Shares Outstanding | 0 | 0 |
| Basic Shares Outstanding | 0 | 0 |
| Dividend Payout Ratio | - | - |
High Cash Burn Rate
As reported in initial financial filings, YD Bio generated a minimal $510,360 in TTM revenue, reflecting an early-stage diagnostic profile that currently lacks the recurring subscription or long-term contract revenue streams typically observed in more mature biotechnology firms operating within the liquid biopsy and regenerative medicine sectors.
The current revenue figure appears to be derived from transactional pilot programs rather than a scalable commercial product. Investors should monitor whether these early-stage diagnostic kit sales can transition into a sustainable, recurring revenue model as the company expands its hospital partnerships.
Based on the company's reported figures, YD Bio maintains a gross margin of 30.44%, which suggests that the cost of goods sold, likely driven by manual laboratory labor and specialized reagents, remains disproportionately high relative to the current pricing of its early-stage diagnostic offerings.
This margin profile appears structurally weak for a biotechnology entity, indicating that the transition from manual laboratory-developed tests to automated, high-throughput diagnostic kits is essential for future margin expansion. The current cost structure implies that the firm has yet to achieve the economies of scale necessary to improve its unit economics.
According to the firm's financial disclosures, YD Bio operates with an operating margin of -286.45%, a figure that highlights a high-burn business model where research and development personnel and specialized equipment costs significantly exceed the company's current revenue generation capabilities during this initial development phase.
The substantial operating deficit suggests an aggressive expenditure strategy that prioritizes rapid technical development over near-term fiscal stability. This cost structure warrants further investigation into whether R&D expenses are being fully expensed or if capitalization practices might be masking the true extent of the company's cash burn.
As noted in recent market analysis, the company's simultaneous pursuit of both cancer diagnostics and regenerative ophthalmology may create significant operational focus risks, potentially leading to faster-than-expected cash depletion given the $3.1M cash reserve and the distinct technical requirements for each of these two separate business segments.
While the market may view the exosome platform as a versatile asset, the technical divergence between detection and regeneration suggests that synergies may be more limited than assumed. Investors should remain cautious regarding the potential for capital dilution if management fails to achieve clinical milestones before the current cash runway is exhausted.
Quick answers to the most common questions about buying YDESW stock.
For fiscal year 2024, YD Bio Limited Warrants (YDESW) reported total revenue of $0.5M. This represents a 45.8% increase compared to $0.4M in 2023.
YD Bio Limited Warrants (YDESW) reported a net loss of $1.4M for the fiscal year ending 2024.
YD Bio Limited Warrants (YDESW) reported an operating income of $-1.5M, resulting in an operating profit margin of -286.5%. This margin reflects the operational efficiency of the business before interest and taxes.
YD Bio Limited Warrants (YDESW) generated $0.2M in gross profit for the year, representing a gross profit margin of 30.4%. This demonstrates the company's core pricing power and production efficiency.